Clinical trials: Recurrent Cervical Carcinoma, open to volunteers
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recurrent or Metastatic Head and Neck Carcinoma
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT07686588
- Testing
- Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
- Volunteers
- 20 people
- Sponsor
- Biying Chen
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Cervix Cancer, Cadonilimab
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix
The goal of this clinical trial is to evaluate the safety and effectiveness of AK104 (Cadonilimab) combined with chemotherapy (cisplatin or carboplatin, and etoposide) for the treatment of recurrent or metastatic small cell…
- Conditions
- Cervix Cancer, Cadonilimab, Small Cell Neuroendocrine Carcinoma of the Cervix
- Trial name
- NCT06810895
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ding Ma
Cervical Cancer, HPV-Related Carcinoma
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
- Conditions
- Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma
- Trial name
- NCT06157151
- Testing
- PRGN-2009 plus Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Precigen, Inc
Head and Neck Squamous Cell Carcinoma
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment…
- Trial name
- NCT06494995
- Testing
- Cadonilimab, Low-dose radiotherapy, SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease, Recurrent Nasopharyngeal Carcinoma, Maximum Tolerated Dose
- Trial name
- AlloNK1 (NCT07247201)
- Testing
- Allogenic expanded Natural Killer Cells (AlloNK1)
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- Singapore General Hospital
Cervical Cancer Recurrent, Radiotherapy
HPV After chemoRadioTherapy
The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT)…
- Conditions
- Cervical Cancer Recurrent, Radiotherapy, Cell Free DNA, HPV
- Trial name
- HART (NCT07493928)
- Where
- Czechia
- Volunteers
- 120 people
- Sponsor
- General University Hospital, Prague
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
This is a phase II trial of aspirin and paclitaxel in patients with recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) who have received prior platinum and PD-1 inhibitor treatment and have an alteration in…
- Conditions
- Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
- Trial name
- APAC (NCT07901803)
- Testing
- Aspirin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Head & Neck Squamous Cell Carcinoma
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with…
- Trial name
- POST-BIO (NCT07485296)
- Testing
- Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., Pembolizumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinomas, Solid Tumor
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerance, pharmacokinetic characteristics and preliminary effectiveness of BL-B16D1 in recurrent…
- Trial name
- NCT06469008
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Nasopharyngeal Carcinoma
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and…
- Trial name
- NCT07412314
- Testing
- Proton therapy, Proton radiation therapy
- Where
- 2 sites in China
- Volunteers
- 52 people
- Sponsor
- Guangzhou Concord Cancer Center
Uterine Cervical Neoplasm
ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer
This study aims to evaluate the clinical feasibility of first-line immunochemotherapy for stage IVB and recurrent cervical cancer guided by circulating tumor DNA (ctDNA), in order to explore the optimal treatment duration or…
- Trial name
- NCT06878196
- Testing
- cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University